Jazz Pharmaceuticals will buy Actio Biosciences for $820 million upfront and up to $500 million more if certain milestones are met for its ultra-rare epilepsy drug.
Jazz Pharmaceuticals CEO Renee Gala (L) and Actio Biosciences CEO David Goldstein
August 10, 2026 09:45 AM EDT
Jazz bets on epilepsy again by acquiring Actio for $820M upfront
Jazz Pharmaceuticals will buy Actio Biosciences for $820 million upfront and up to $500 million more if certain milestones are met …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Actio Biosciences, which will receive $820 million up front in the deal, adds to a major upswing in private biotech buyouts seen…
Jazz Pharmaceuticals will acquire Actio Biosciences, Inc., a deal that expands Jazz's pipeline and presence in rare epilepsy…
Jazz Pharmaceuticals teams with AbCellera on cancer therapies as analysts maintain positive targets despite a recent Zepzelca…
The potentially $4 billion collaboration is the latest example of drugmakers working to broaden the use of T cell engagers,…
AbCellera and Jazz Pharmaceuticals strike a preclinical T cell engager deal worth up to $4.1B targeting gastrointestinal and…
Jazz Pharmaceuticals (JAZZ) reported Q2 sales above estimates and raised its FY26 sales guidance. Analysts have mixed opinions,…
